Clinical Observation of ZD1839 in the Treatment of Advanced Non-small-cell Lung Cancer

Objective:To observe the curative effect and adverse event of non-small cell lung cancer(NSCLC) patients who took ZD1839.Methods:We chose 43 patients who took ZD1839 and invested the curative effect and adverse event after 90 days.Results:In the 43 patients,CR,PR,SD rate were 2.3%,16.3%,32.6% respectively.Disease control rate was 51.2%.Adverse events:rash,diarrhea,step-up of aminotransferase,nausea and vomiting were reported by 48.8%,27.9%,11.6% and 14.0% respectively.No interstitial lung disease was found.Conclusion:We confirm ZD1839 is a new drug which can be adapted to tumor patients according to its disease control rates and adverse events.It shows good prospect to patient which suffer from advanced and metastatic tumor.